Welcome to our dedicated page for Viking Therapeutics SEC filings (Ticker: VKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Viking Therapeutics, Inc. filings document a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. Recent Form 8-K reports furnish quarterly and year-end financial results, corporate updates, and clinical-development disclosures for VK2735, including subcutaneous and oral obesity programs, trial results, and related regulatory communications.
The company's proxy materials disclose board and shareholder-voting matters, executive compensation, equity awards, and pay-versus-performance information. Viking's SEC record also covers Regulation FD communications, clinical-development updates, cash resources, and governance matters tied to a development-stage biotechnology issuer.
Viking Therapeutics reported that Chief Medical Officer Hubert C. Chen received a grant of stock options. The award covers 190,000 options to buy common stock at an exercise price of $31.27 per share, expiring on June 1, 2036. According to the vesting terms, 25% of the options vested immediately on the grant date, with an additional 25% vesting on each one-year anniversary over the next three years. Following this compensation-related grant, Chen holds 190,000 stock options directly.
Viking Therapeutics, Inc. filed an initial ownership report for Chief Medical Officer Chen Hubert C on Form 3. The filing lists him as an officer but shows no reported transactions, meaning it simply establishes his status as an insider for future ownership and trading disclosures.
Viking Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Of the 115,893,943 common shares outstanding as of March 20, 2026, 80,089,532 shares were represented, about 69.1% of shares entitled to vote, establishing a quorum.
Stockholders elected Class II directors J. Matthew Singleton and S. Kathryn Rouan, Ph.D., to serve until the 2029 annual meeting or until their successors are elected and qualified. They also ratified the selection of CBIZ CPAs P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026.
On an advisory basis, stockholders approved the compensation of the company’s named executive officers as disclosed in the proxy statement. These outcomes confirm continuity in Viking’s board composition, auditor relationship, and executive pay program.
Vanguard Capital Management reported beneficial ownership of 5,877,263 shares of Viking Therapeutics Inc. common stock (5.08% of the class) as of 03/31/2026. The filing shows sole voting power of 864,761 shares and sole dispositive power over 5,877,263 shares, and states these holdings include securities held for Vanguard funds and managed accounts.
Viking Therapeutics reported a much larger quarterly loss as it ramped up late‑stage obesity trials and faced a new licensing dispute. For the three months ended March 31, 2026, the company recorded a net loss of $158.3 million, compared with $45.6 million a year earlier, driven mainly by higher research and development spending.
R&D expenses rose to $150.2 million as Viking advanced its Phase 3 VANQUISH-1 and VANQUISH-2 studies of obesity drug VK2735 and continued work on other metabolic programs. The company ended the quarter with $118.1 million in cash and $484.8 million in short‑term investments, supporting an equity base of $501.9 million. Viking also highlighted a dispute with Ligand Pharmaceuticals, which has notified Viking that it is purporting to terminate the license for the TR‑Beta program, including VK2809; Viking states it believes Ligand has no such right and plans to vigorously defend its position.
Viking Therapeutics reported a larger first quarter 2026 loss as it ramps investment in its obesity pipeline. The company posted a net loss of $158.3 million, or $1.37 per share, compared with a net loss of $45.6 million, or $0.41 per share, a year earlier. Research and development expenses rose to $150.2 million from $41.4 million, while general and administrative costs were roughly flat at $14.0 million.
Viking ended March 31, 2026 with $603 million in cash, cash equivalents and short-term investments, down from $706 million at year-end 2025, supporting continued clinical work. Its Phase 3 VANQUISH trials of subcutaneous VK2735 for obesity are fully enrolled, with more than 4,500 patients in VANQUISH-1 and approximately 1,000 in VANQUISH-2. A Phase 3 trial of oral VK2735 in obesity is planned to start in the fourth quarter of 2026, a maintenance dosing study is ongoing with data expected in the third quarter of 2026, and an IND has been filed for amylin agonist VK3019, with a Phase 1 trial targeted for the second quarter of 2026.
Viking Therapeutics is asking stockholders to vote at its virtual 2026 Annual Meeting on May 19, 2026 at 8:00 a.m. Pacific Time. Holders of 115,893,943 common shares as of March 20, 2026 can vote on electing two Class II directors, ratifying CBIZ CPAs P.C. as auditor for 2026, and approving executive compensation on an advisory basis. The meeting will be held via live webcast and requires a quorum of at least 57,946,972 shares. The proxy statement also outlines board structure, committee responsibilities, director independence and an executive pay program that emphasizes performance-based equity and annual incentives.
The Vanguard Group filed an Amendment No. 3 to Schedule 13G reporting that it beneficially owns 0 shares of Viking Therapeutics Inc common stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538 that caused certain Vanguard subsidiaries or business divisions to report beneficial ownership separately.
The amendment is signed by Ashley Grim, Head of Global Fund Administration, and lists Vanguard's principal business address in Malvern, Pennsylvania.
Viking Therapeutics, Inc. reported that Chief Commercial Officer Neil William Aubuchon purchased common stock in the company. On this transaction date, he made an open-market purchase of 4,475 shares of common stock at $33.50 per share. Following this trade, he directly holds 4,475 shares of Viking Therapeutics common stock.